HER2 FPBMC therapy (University Of Virginia)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameHER2 FPBMC therapy (University Of Virginia)

Drug Alias NameAnti-CD3 x Anti-HER2 Bispecific Antibody (HER2Bi) Armed Fresh Peripheral Blood Mononuclear Cells therapy (University Of Virginia)HER2 FPBMC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Stem cell therapy > Peripheral blood stem cell therapyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-HER2

TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsProstatic NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Virginia

Inactive CompaniesN/A

Active IndicationsProstatic NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A